Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema fell short of some ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.

Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk's website. Please refer to the enclosed notice for the Annual General Meeting for ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group ...